Overview
Founded in 2012 in Belgium, CluePoints applies advanced statistics and machine learning to the problem of data integrity in clinical trials. Pharmaceutical and biotech companies, as well as contract research organizations, use the platform to identify risks, track ongoing issues, and monitor discrepancies throughout the drug development process.
By the time of its EQT transaction, CluePoints had more than 9,500 platform users, had helped de-risk more than 1,600 studies, and detected over 142,000 data issues for its customers. The company's customer base includes many of the top 20 largest pharmaceutical companies globally.
Summit Partners made a significant growth investment in CluePoints in 2020. In June 2024, EQT's Healthcare Growth Strategy and EQT Growth Fund agreed to acquire a majority stake in CluePoints, with meaningful reinvestment from management and existing shareholders Summit Partners and co-founder Clinimetrics SA. The EQT deal marked CluePoints as one of the more notable Belgian healthtech exits of 2024.
Funding history
- Growth investment by Summit Partners2020
- Majority acquisition by EQTJune 2024EQT Healthcare Growth Strategy, EQT Growth Fund
Key people
In the news
- 100% source data verification. 1.1% of data actually corrected. That's the median across a retrospective analysis of 1,168 studies. It doesn't mean SDV has no value. It means applying the same scrutiny to everything may not be an effective way to find the issues that matter most to patient safety and trial reliability. With Phase III protocols now collecting around 5.9 million data points and growing about 11% a year, Sylviane de Viron argues in pharmaphorum that trial complexity is permanent, but uniform oversight doesn't have
- One minute from Tuesday night at Urban Oak. Luis Ortega and Richard Young on what IQD, MSR, and IMC mean for clinical data review, and why a room full of the people who do this work every day was the right place to launch them. Thank you to Luis for the toast and to everyone who joined us to celebrate! #SCDM2026 #ClinicalDataReview #CluePoints #ClinicalDataManagement #ClinicalTrials
- Day one at SCDM US in the books. Our team has been demoing IQD, MSR, and IMC nonstop since the doors opened, and they are doing a fantastic job bringing all three to life on the floor. Thanks to everyone who stopped by today. Stop by booth 502 and see all three for yourself. #SCDM26 #ClinicalDataManagement #ClinicalTrials #RBQM #AIinClinicalResearch
- SCDM 2026 is here, and today is the big one. Three capabilities. One scientific foundation. Visit CluePoints at Booth 502 from 12:00 to 2:00 to see IQD, MSR, and IMC in action. Meet the experts behind them, watch live demos, and stay for the 1:00 champagne toast and the premiere of our launch video. And tonight, we're celebrating the launch at Urban Oak Rooftop Bar from 7:30 to 10:30 with drinks, networking, and skyline views of Raleigh. Register here: https://hubs.ly/Q04xyCHx0 Booth 502 is open through Thursday. #SCDM26
- Medical and safety review is mandatory under ICH-GCP. Most teams still run it as a static, manual exercise: fragmented patient listings, EDC navigation by hand, and query follow-up that lives in email without an audit trail. CluePoints MSR turns it into a live, operational workflow. Data from disparate sources lands on a single review surface. Delta changes and full data point history show reviewers what changed, when, and why. Review progress and coverage are visible rather than assumed. Medical monitors query directly from the
- Our US team swapped dashboards for ballpark seats this week and headed to Citizens Bank Park to cheer on the Phillies. Good food, good company, and a reminder that the people behind the technology matter just as much as the technology itself. And of course, go Phils! #CluePoints #LifeAtCluePoints #Phillies
- Now available on demand: one of the industry's first peer-reviewed studies on the financial return of RBQM. You can watch the research, not just read the paper. On September 10, Ken Getz and Abigail Dirks, MS of Tufts Center for the Study of Drug Development joined Sylviane de Viron of CluePoints to walk through the findings, published in Therapeutic Innovation & Regulatory Science. Drawing on real-world data from 18 oncology trials, the session covered: → How organizations achieved up to 23x ROI on their RBQM investment → How
- Looking forward to Sylviane de Viron's session at the 4th Annual ACDM RBQM Symposium. Historical trial data has far more to say about where quality risks arise than most teams are using today.
Open roles (6)
- Senior Consolidation AccountantSep 3, 2026
- Director of FP&AAug 4, 2026
- Chief of Staff to the CTPOJul 23, 2026
- AI First Product OwnerJul 9, 2026
- Senior Software Engineer - AI FirstOttignies-Louvain-la-Neuve · Jun 29, 2026
- SRE Cloud Infrastructure Engineer (Poland)May 6, 2026
Alumni 4 went on to found or lead
Gregoire De HemptinneCTO and Software architect→Co-founder and CEO at Shayp
Laurent BRISBOISBackend Software Engineer→Co-Founder at Hubbiz
Luca DerumierMachine Learning Engineer→Co-Founder at Codika
Quentin DugauthierIT Coordinator→Chief Operating Officer at Digazu - PipeStore
Something wrong or missing? Send an update. Fixed within 24 hours.